Lab21 Wins Biomedical Project of the Year Award
Lab21’s MycAssay Aspergillus and MycAssay Pneumocystis are the world’s first commercial PCR assays for pulmonary fungal infections. A recent evaluation of MycAssay Aspergillus has shown it to be a sensitive and specific molecular test for the diagnosis of invasive aspergillus.
Hayden Jeffreys, Divisional Director of Products, Lab21 said: “This award for the MycAssay product line recognises the importance of Lab21’s tests for Aspergillus and Pneumocystis, the first products in what is rapidly becoming a portfolio of real-time PCR tests for serious invasive fungal diseases We are pleased with the adoption of these assays into routine use, already demonstrated by increasing sales into 14 countries.”
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.